Protocol for the CUPIDO trials; multicenter randomized controlled trials to assess the value of combining prolapse surgery and incontinence surgery in patients with genital prolapse and evident stress incontinence (CUPIDO I) and in patients with genital prolapse and occult stress incontinence (CUPIDO II).
BACKGROUND
About 40% of all patients with genital prolapse report stress-incontinence. In about half of the 60% patients that do not report stress-incontinence, occult urinary stress-incontinence can be detected. In these patients stress-incontinence is masked due to kinking or compression of the urethra by the prolapse.In case surgical correction is indicated there are two strategies to manage patients with combined prolapse and (occult) stress incontinence. This strategy is either (i) a combination of prolapse surgery and stress-incontinence surgery or (ii) to correct the prolapse first and evaluate afterwards whether additional stress-incontinence surgery is indicated. The advantage of combining prolapse and stress-incontinence surgery is that only few patients report stress-incontinence following such combination. However, this combination has been associated with an increased risk on complications, of which the development of obstructive micturition symptoms, overactive bladder symptoms and bladder retention are the most important ones. Furthermore, combining two procedures may be unnecessary as performing only prolapse surgery may cure stress-incontinence. In the randomized CUPIDO trials both strategies are compared in patients with prolapse and evident stress incontinence (CUPIDO I trial) and in patients with prolapse and occult stress incontinence (CUPIDO II trial).


METHODS
The CUPIDO trials are two multicenter randomized controlled trials in which women with stress urinary incontinence (SUI) or occult stress urinary incontinence (OSUI) are randomized to prolapse surgery combined with anti incontinence surgery (concomitant surgery) or to prolapse surgery only. Patients with at least stage 2 POP are eligible, women with evident SUI are randomized in CUPIDO I. Patients without SUI are eligible for CUPIDO II and will have urodynamic evaluation or a standardized redression test. Women with OSUI are randomized, women without OSUI are followed up but not randomized. The primary outcome measure is absence of SUI twelve months after surgery. Furthermore, economic evaluations are conducted, and the effectiveness of urodynamic investigation is evaluated against a non-invasive way to determine SUI in women with POP. A total of 450 women will be included in the study.


BACKGROUND
Trial registration http://www.trialregister.nl NTRR 1197 en 1070.
van der Steen
Annemarie
A
Department of Obstetrics and Gynaecology, University Medical Centre Groningen, PO Box 30.001, 9700 RB, Groningen, the Netherlands. a.vdsteen@yahoo.com
van der Ploeg
Marinus
M
Dijkgraaf
Marcel G W
MG
van der Vaart
Huub
H
Roovers
Jan-Paul W R
JP
D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D018570:Risk Assessment; D014550:Urinary Incontinence, Stress / Q000601:surgery*; D014596:Uterine Prolapse / Q000601:surgery*
Am J Obstet Gynecol. 2005 May;192(5):1537-43
15902154
Br J Obstet Gynaecol. 1982 Jun;89(6):459-63
7082603
Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jan;17(1):27-9
16094506
BJU Int. 2002 Jun;89(9):863-7
12010229
Cochrane Database Syst Rev. 2002;(3):CD003195
12137680
N Engl J Med. 2006 Apr 13;354(15):1557-66
16611949
Qual Life Res. 1994 Oct;3(5):291-306
7841963
Acta Obstet Gynecol Scand. 2003 Nov;82(11):1049-53
14616280
Acta Obstet Gynecol Scand. 1989;68(6):545-9
2520812
Clin Obstet Gynecol. 1998 Sep;41(3):777-85
9742373
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Apr;18(4):437-42
16909194
Int J Gynaecol Obstet. 2007 Apr;97(1):31-4
17291508
Med Care. 1997 Nov;35(11):1095-108
9366889
Int Urogynecol J. 2010 Feb;21(2):179-86
19940978
Neurourol Urodyn. 2003;22(2):97-104
12579625
Am J Obstet Gynecol. 2002 Jun;186(6):1292-5; discussion 1295-8
12066111
Am J Obstet Gynecol. 2000 Jun;182(6):1378-81
10871452
Eur Urol. 2004 Mar;45(3):356-61
15036683
Acta Obstet Gynecol Scand. 2004 Oct;83(10):950-4
15453892
Eur J Obstet Gynecol Reprod Biol. 2002 Jul 10;103(2):163-7
12069741
Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1574-8
16038162
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Apr;18(4):455-60
17120169
Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jan;17(1):60-5
15965574
Int J Technol Assess Health Care. 1996 Summer;12(3):405-15
8840661